Finance

Lists
SRPT:NASDAQ
Sarepta Therapeutics Inc
$ 19.30
+7.10%
(+1.28) 1D
8-р сарын 19, 13:54:29 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SRPT...
Open
$ 18.74
High
$ 20.19
Low
$ 18.74
Mkt. cap
2.05 тэрбум
Avg. vol.
3.00 сая
Volume
2.69 сая
52-wk high
$ 25.32
52-wk low
$ 14.69
EPS
-$ 1.66
Beta
0.24
Shares outstanding
105.63 сая
No. of employees
835
Open
$ 18.74
High
$ 20.19
Low
$ 18.74
Mkt. cap
2.05 тэрбум
Avg. vol.
3.00 сая
Volume
2.69 сая
52-wk high
$ 25.32
52-wk low
$ 14.69
EPS
-$ 1.66
Beta
0.24
Shares outstanding
105.63 сая
No. of employees
835
News stories
From web sources and news partners
Profile
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs. Wikipedia
About Sarepta Therapeutics Inc
CEODouglas S. Ingram
Employees835
Founded1980
Headquarters-
Sector-
Websitesarepta.com
Analyst ratings
Based on 16 analysts giving stock ratings to SRPT in the past 3 months
Hold
Buy
5
Hold
7
Sell
4
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for SRPT in the last 3 months.
Highest
Current $ 19.30
$ 38.00 (+96.89%)
Average
$ 22.87 (+18.50%)
Lowest
$ 5.00 (-74.09%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gavin Clark-Gartner
Evercore ISI
Hold
Maintained
$ 19.00
-1.6%
08/10/2026
Eliana Merle
Barclays
Hold
Maintained
$ 20.00
+3.6%
08/07/2026
Tazeen Ahmad
Bank of America Securities
Sell
Reiterated
$ 18.00
-6.7%
08/06/2026
Kristen Kluska
Cantor Fitzgerald
Hold
Maintained
$ 21.00
+8.8%
08/05/2026
Kostas Biliouris
Oppenheimer
Buy
Maintained
$ 35.00
+81.3%
08/06/2026
Brian Abrahams
RBC Capital
Hold
Maintained
$ 19.00
-1.6%
08/05/2026
Yun Zhong
Wedbush
Buy
Reiterated
$ 35.00
+81.3%
08/06/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
$ 38.00
+96.9%
08/06/2026
Michael Ulz
Morgan Stanley
Hold
Reiterated
$ 25.00
+29.5%
08/06/2026
Biren Amin
Piper Sandler
Hold
Maintained
$ 20.00
+3.6%
08/06/2026
Mitchell Kapoor
H.C. Wainwright
Sell
Reiterated
$ 5.00
-74.1%
08/06/2026
Gil Blum
Needham
Sell
Reiterated
-
-
08/06/2026
Ritu Baral
TD Cowen
Hold
Reiterated
$ 17.00
-11.9%
08/06/2026
Yigal Nochomovitz
Citi
Sell
Maintained
$ 13.00
-32.6%
07/20/2026
Uy Ear
Mizuho Securities
Buy
Maintained
$ 31.00
+60.6%
07/10/2026
Andy Chen
Wolfe Research
Buy
Upgraded
$ 27.00
+39.9%
07/08/2026
Anupam Rama
J.P. Morgan
Hold
Maintained
$ 19.00
-1.6%
05/18/2026
Stephen Brozak
WBB Securities
Buy
Maintained
$ 38.00
+96.9%
03/26/2026
Unknown Analyst
WBB Securities
Buy
Maintained
$ 38.00
+96.9%
03/26/2026
David Hoang
Deutsche Bank
Sell
Maintained
$ 14.00
-27.5%
03/26/2026
William Pickering
Bernstein
Hold
Maintained
$ 20.00
+3.6%
03/25/2026
Joseph Schwartz
Leerink Partners
Hold
Maintained
$ 15.00
-22.3%
03/25/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$ 19.00
-1.6%
03/09/2026
Brian Skorney
Robert W. Baird
Hold
Maintained
$ 20.00
+3.6%
02/26/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
$ 17.00
-11.9%
02/25/2026
Sami Corwin
William Blair
Hold
Reiterated
-
-
02/26/2026
Last report
2026 оны 8-р сарын 5
Fiscal period
Q2 2026
EPS / Est. (USD)
$ 0.64 / $ 0.48
+32.49%beat
Revenue / Est. (USD)
401.25 сая / 369.62 сая
+8.56%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
399.36 сая
442.93 сая
730.80 сая
401.25 сая
Cost of goods sold
369.66 сая
724.04 сая
262.73 сая
157.89 сая
Cost of revenue
369.66 сая
724.04 сая
262.73 сая
157.89 сая
Research and development expenses
-
-
-
82.75 сая
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
91.89 сая
128.30 сая
108.95 сая
107.60 сая
Operating expense
92.57 сая
128.97 сая
109.64 сая
191.07 сая
Total operating expenses
462.24 сая
853.02 сая
372.37 сая
348.96 сая
Operating income
-62.88 сая
-410.08 сая
358.43 сая
52.29 сая
Other non operating income
-702.00 мян
-338.00 мян
1.16 сая
-246.00 мян
EBT including unusual items
-194.05 сая
-278.30 сая
343.17 сая
-1.75 сая
EBT excluding unusual items
-63.90 сая
-423.20 сая
344.24 сая
36.74 сая
Income tax expense
-14.10 сая
4.55 сая
12.22 сая
3.14 сая
Effective tax rate
7.27%
-1.64%
3.56%
-179.59%
Other operating expenses
-
-
-
-
Net income
-179.95 сая
-282.85 сая
330.96 сая
-4.89 сая
Net profit margin
-45.06%
-63.86%
45.29%
-1.22%
Earnings per share
-0.13
-3.58
3.16
0.64
Interest and investment income
7.25 сая
8.07 сая
6.36 сая
6.21 сая
Interest expense
-7.56 сая
-20.84 сая
-21.71 сая
-21.51 сая
Net interest expenses
-316.00 мян
-12.77 сая
-15.35 сая
-15.30 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
-44.43 сая
-404.83 сая
369.03 сая
62.70 сая
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google аппс